Foghorn Q1 net loss $19.9M, cash $183.6M; FHD-909 Phase 1 on track; IND for two degraders expected 2027

Foghorn Therapeutics Inc.

2026-Q1 EPS reported -$0.29 revenue$3,267,000

Q1 2026 net loss $19.9M (vs $18.8M loss Q1 2025); collaboration revenue $3.3M (down from $6.0M).
Cash, equivalents & marketable securities $183.6M as of Mar 31, 2026; cash runway into H1 2028.
Lead program FHD-909 Phase 1 dose-escalation on track; preclinical combo with anti-PD-1 showed complete tumor regression and immune memory.
IND expected 2027 for Selective CBP degrader FHT-171 and Selective EP300 degrader; ARID1B degrader advancing to in vivo proof-of-concept in 2026.
R&D expenses declined to $18.3M (from $21.6M) driven by lower Lilly-partnered program costs and facilities expenses.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Foghorn Therapeutics Inc. reported financial results for the quarter ended March 31, 2026.

Period: the quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 7, 2026, Foghorn Therapeutics Inc. (the “Company”) issued a press release announcing certain of the Company’s financial results for the quarter ended March 31, 2026.

View on SEC.gov

Browse all earnings releases →

Foghorn Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-26-031669

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.